Lidocaïne test for easier and less time consuming assessment of liver function in several hepatic injury models

Saïd, Dorra Ben; Ali, Ridha Ben; Ferchichi, Henda; Salouage, Issam; Ouanes, Lobna; Gaïes, Emna; Trabelsi, Sameh; Kooli, Emna; Kourda, Nadia; Abdelmoula, J.; Lakhal, Mohamed; Klouz, Anis

doi:10.1007/s12072-011-9270-2

Cited by 7 publications

(2 citation statements)

References 28 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The galactose elimination capacity (GEC) and lidocaine metabolism tests correlate modestly with MELD and CTP . Both lidocaine catabolism and the appearance of its metabolite, monoethylglycinexylidide (MEGX), change in proportion to hepatic injury in animal models . MEGX synthesis, and galactose and sorbitol elimination, reflect the viability of primary hepatocyte cultures .…”

Section: The Use Of Metabolic Tests In Assessing the Severity Of Livementioning

confidence: 99%

Potential use of metabolic breath tests to assess liver disease and prognosis: has the time arrived for routine use in the clinic?

Stravitz

Ilan

2016

Liver International

View full text Add to dashboard Cite

The progression of liver disease may be unique among organ system diseases in that progressive fibrosis compromises not only the sufficiency of hepatocyte mass but also impairs blood flow to the liver, resulting in porto-systemic shunting. Although liver biopsy as an assessment of fibrosis has become the key biomarker of and target for new therapies, it is invasive and subject to sampling error, and cannot quantify metabolic function or porto-systemic shunting. Measurement of the hepatic venous pressure gradient accommodates some of the deficiencies of biopsy but requires expertise not widely available and misses minor changes in hepatocellular mass and thereby information about metabolic function. Thus, an unmet need in clinical hepatology remains unfulfilled: a noninvasive biomarker which quantitates both the hepatocellular insufficiency and porto-systemic shunting inherent in progressive hepatic fibrosis. Ideally, such a biomarker should correlate with clinical endpoints including liver-related survival and cirrhotic complications, be performed at the point-of-care, and be affordable and easy to use. This review, an expert opinion, summarizes background and recent data suggesting that metabolic breath tests may now meet these requirements and have a valid place in clinical hepatology to supplant the time-honoured assessment of hepatic fibrosis. K E Y W O R D Sbreath tests, fibrosis, liver function, methacetin

show abstract

Section: The Use Of Metabolic Tests In Assessing the Severity Of Livementioning

confidence: 99%

Potential use of metabolic breath tests to assess liver disease and prognosis: has the time arrived for routine use in the clinic?

Stravitz

Ilan

2016

Liver International

View full text Add to dashboard Cite

show abstract

“…Formation rates of MEGX decrease with increasing severity of liver disease, and correlation of MEGX single point concentration with Child-Pugh class has been shown [15] [16] . Since the optimal time for blood sampling varies between studies (15, 30 or 60 minutes), the results of previous studies are inconsistent about the use of MEGX concentration measurement at a fixed time point after LID administration as an indicator of metabolic hepatic activity [11] [12] [13] [17] [18] . Single MEGX concentration is static indicator of liver function characterized by wide interindividual variability, whereas pharmacokinetic parameters based on LID time-depending levels might be better predictors of hepatic function [7] [19] [20] .…”

Section: Introductionmentioning

confidence: 99%

Lidocaine clearance as pharmacokinetic parameter of metabolic hepatic activity in patients with impaired liver

Jovanović¹,

Kovačević²,

Kovačević³

et al. 2023

J Med Biochemistry

View full text Add to dashboard Cite

Background The study aimed to estimate lidocaine (LID) pharmacokinetic parameter values in patients with impaired liver function, and to assess change in parameters related to the surgical intervention. Methods Patients with impaired liver function were subject to the test prior to, 3 and 7 days after the intervention. LID was administered in single i.v. dose of 1 mg/kg. Blood samples were collected at 15, 30 and 90 minutes after drug administration. Non-compartmental analysis was applied for calculating the pharmacokinetic parameters. Results The study included 17 patients with the diagnosis of cirrhosis and 41 patients with liver tumor. In both groups of patients, the values of the coefficients of correlation show the best correlation between CL and Child-Pugh score (-0.693, p<0.005) over other pharmacokinetic parameters. The results indicate worsening hepatic function on 3rd day after operation in comparison to the values of LID CL prior to operation (mean LID CL for patients with Child-Pugh class A are 25.91 L/h, 41.59 L/h, respectively; while for B class are 16.89 L/h, 22.65 L/h, respectively). On day 7th, the values of LID CL (mean value for patients with Child-Pugh class A and B are 40.98 L/h and 21.46 L/h, respectively) are increased in comparison to 3rd day after. Conclusions LID pharmacokinetic parameters consequently changed according to the severity of liver impairment, assessed by Child-Pugh score. Values of LID CL and Vd coupled with standard biochemical parameters may be used in obtaining the complete picture of hepatic status of patients.

show abstract

Preoperative Evaluation of Liver Function

Cieslak

Bennink

Gulik

2017

Extreme Hepatic Surgery and Other Strategies

View full text Add to dashboard Cite

Lidocaïne test for easier and less time consuming assessment of liver function in several hepatic injury models

Abstract: Our method provides reliable and reproducible results using only a small portion of liver which allows for a fast and easy assessment of liver metabolic capacity. Moreover, our method presents an alternative to the in vivo technique and seems more feasible in a clinical setting.

Cited by 7 publications

References 28 publications

Potential use of metabolic breath tests to assess liver disease and prognosis: has the time arrived for routine use in the clinic?

Potential use of metabolic breath tests to assess liver disease and prognosis: has the time arrived for routine use in the clinic?

Lidocaine clearance as pharmacokinetic parameter of metabolic hepatic activity in patients with impaired liver

Preoperative Evaluation of Liver Function

Contact Info

Product

Resources

About